Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

por Agar, Camille, Geier, Margaux, Léveiller, Guillaume, Lamy, Régine, Bizec, Jean-Louis, Tiercin, Marie, Bernier, Cyril, Robinet, Gilles, Léna, Hervé, Ricordel, Charles, Corre, Romain
Publicado 2020

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)

por Renaud, Emmanuelle, Ricordel, Charles, Corre, Romain, Leveiller, Guillaume, Gadby, Florence, Babey, Hélène, Annic, Josselin, Lucia, François, Bourbonne, Vincent, Robinet, Gilles, Descourt, Renaud, Orione, Charles, Quéré, Gilles, Geier, Margaux
Publicado 2023

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

por Geier, Margaux, Descourt, Renaud, Corre, Romain, Léveiller, Guillaume, Lamy, Régine, Goarant, Éric, Bizec, Jean‐Louis, Bernier, Cyril, Quéré, Gilles, Amrane, Karim, Gaye, Elisabeth, Lucia, François, Burte, Emilie, Chouaid, Christos, Robinet, Gilles
Publicado 2020

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

por Amrane, Karim, Geier, Margaux, Corre, Romain, Léna, Hervé, Léveiller, Guillaume, Gadby, Florence, Lamy, Régine, Bizec, Jean‐Louis, Goarant, Eric, Robinet, Gilles, Gouva, Sylvie, Quere, Gilles, Abgral, Ronan, Schick, Ulrike, Bernier, Cyril, Chouaid, Christos, Descourt, Renaud
Publicado 2020